Executive Editor, The American Journal of Managed Care
Mary Caffrey is the Executive Editor of The American Journal of Managed Care (AJMC). With a focus on managed care and healthcare delivery, Mary's work covers a wide range of topics including new guidelines in oncology, value-based care, clinical trial data, and the management of various diseases. Her articles provide insights and analysis for healthcare professionals and researchers in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Mary Caffrey's coverage predominantly focuses on healthcare and pharmaceuticals, specifically within the field of oncology. Her articles heavily rely on data and press releases, indicating a preference for factual information from credible sources. Sources with access to relevant clinical trial or real-world data could be particularly valuable in reaching out to her.
Given the technical nature of the topics covered, experts who can provide insights into new research findings, medical breakthroughs, or trends within oncology would likely capture Mary's interest.
While she does not have a specific geographic focus, it is essential that pitches are based on substantial scientific evidence and contribute meaningfully to ongoing conversations in oncology and related fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mary Caffrey
Research presented at the 66th American Society of Hematology Annual Meeting revealed that a genetic variant enriched in Andean populations, associated with reduced inflammation and improved response to ropeginterferon-α, could guide more precise treatments for polycythemia vera (PV) and essential thrombocythemia.
By: Mary Caffrey
The inMIND trial was the first to examine dual targeting of CD19 and CD20 in follicular lymphoma.
By: Mary Caffrey
The study is the first to evaluate a fixed-duration regimen of venetoclax, the first-generation BCL2 inhibitor, with a second-generation Bruton tyrosine kinase inhibitor, acalabrutinib, in chronic lymphocytic leukemia (CLL).
By: Mary Caffrey
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
By: Mary Caffrey
Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can bring responses even in Stage III patients.
By: Mary Caffrey
The American Society of Hematology is launching health equity effort, "Treating Fairly," which was discussed at the quality symposium at the 66th Annual Meeting & Exposition.
By: Mary Caffrey
Haydar Frangoul, MD, MS, medical director, Pediatric Hematology/Oncology for Sarah Cannon Research Institute at TriStar Centennial Children's Hospital, Nashville, presented the data on the long-term efficacy and safety for participants with sickle cell disease (SCD) who received exa-cel.
By: Mary Caffrey
Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of phlebotomy in younger patients with polycythemia vera, the promise of vaccines, and the unmet potential of pegylated interferons.
By: Mary Caffrey, Laura Joszt
Key Takeaways Innovations in cancer care are overshadowed by financial concerns, with high out-of-pocket costs limiting access to essential services.
By: Mary Caffrey
Listen Key Takeaways The 2023 chemotherapy shortage led to a 60% drop in cisplatin use for head and neck cancer, with costly substitutes increasing treatment expenses.
(833) 317-6278 
